HopeStage
Back to all studies
CompletedNCT00363337

Aripiprazole for depression in bipolarity

About this titleRead the official source — NCT00363337
Medication studyAges 18+United States
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
CincinnatiSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateAugust 2006
Recruitment status
Completed
Enrollment listed in the registry
31
Sponsor
Lindner Center of HOPE
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
Over 18 Years
Official registry ID
NCT00363337
Official title
Show the full official title

A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cincinnati

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Lindner Center of HOPE.

Did this study involve medication?

Yes. The study involved medication, including aripiprazole.

Who was this study for?

This study was for people with bipolarity. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies